Journal
MOLECULAR PHARMACEUTICS
Volume 5, Issue 4, Pages 548-558Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp800003u
Keywords
alendronate; biodistribution; bone targeting; drug delivery; HPMA copolymer; pharmacokinetics
Funding
- NIAMS NIH HHS [R01 AR053325, AR053325] Funding Source: Medline
- NIGMS NIH HHS [GM069847, R01 GM069847] Funding Source: Medline
Ask authors/readers for more resources
The biodistribution and pharmacokinetics of bone-targeting N-(2-hydroxypropyl)-methacrylamide (HPMA) copolymer-alendronate conjugates were evaluated following intravenous administration of radioiodinated conjugates to young healthy BALB/c mice. The synthesis of a polymerizable and cathepsin K cleavable alendronate derivative, N-methacryloylglycyl-cylprolylnorleucylalendronate, enabled the preparation of HPMA copolymer-alendronate conjugates with varying composition. Using the RAFT (reversible addition-fragmentation chain transfer) polymerization technique, four conjugates with different molecular weight and alendronate content and two control HPMA copolymers (without alendronate) with different molecular weight were prepared. The results of biodistribution studies in mice demonstrated a strong binding capacity of alendronate-targeted HPMA copolymer conjugates to bone. Conjugates with low (1.5 mol%) alendronate content exhibited a similar bone deposition capacity as conjugates containing 8.5 mol % of alendronate. The molecular weight was an important factor in the biodistribution of the HPMA copolymer conjugates. More conjugate structures need to be evaluated, but the data suggest that medium molecular weights (50-100 kDa) might be effective drug carriers for bone delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available